Zydus Cadila receives USFDA approval for Glyburide and Metformin HCL tablets

Zydus Cadila has received final USFDA approval to sell anti-diabetics Glyburide and Metformin Hcl tablets in in strengths of 1.25/250, 2.5/500 and 5/500 mg in the American market. The company will produce the drug at its manufacturing site at Baddi. The group now has 103 approvals and has so far filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, Cadila Healthcare.

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*